Home
Resources
Publications
Calcipotriene and Betamethasone Dipropionate for the Topical Treatment of Plaque Psoriasis

Calcipotriene and Betamethasone Dipropionate for the Topical Treatment of Plaque Psoriasis

Kevin C Kin, Dane Hill, Steven R Feldman

Expert Rev Clin Pharmacol. 2016 Jun;9(6):789-97.

PMID: 27089906

Abstract:

Introduction:
Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment.
Areas covered:
Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations. Phase II and III clinical trials have consistently shown the two-compound formulation to be effective and safe, with no clinically significant skin atrophy, calcium level changes, or adrenal suppression were seen. Topical scalp solution was also safe and effective in treating scalp psoriasis in pediatric populations. Expert commentary: Calcipotriene plus BD is more effective and safer than the individual ingredients in the same vehicle for treating body and scalp psoriasis. It should be considered a first line therapy for mild-to-moderate plaque psoriasis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP5593204-A	Betamethasone Dipropionate		5593-20-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: